Literature DB >> 2272219

Scleroderma esophagus.

S R Fulp1, D O Castell.   

Abstract

Scleroderma (systemic sclerosis) is a connective tissue disorder characterized by thickening and fibrosis of the skin and visceral involvement that may include the heart, lungs, kidneys, and gastrointestinal tract. At least 40-50% of patients with scleroderma experience esophageal symptoms such as heartburn and dysphagia, while up to 90% of patients have esophageal dysfunction on objective testing at some point in their disease. The disease results in smooth muscle dysfunction that causes esophageal aperistalsis and reduced lower esophageal sphincter pressures. Gastroesophageal reflux with poor acid clearance results with an increased incidence of complications such as peptic stricture and Barrett's esophagus. Aggressive medical therapy is necessary to prevent these and other complications of gastroesophageal reflux.

Entities:  

Mesh:

Year:  1990        PMID: 2272219     DOI: 10.1007/bf02412688

Source DB:  PubMed          Journal:  Dysphagia        ISSN: 0179-051X            Impact factor:   3.438


  48 in total

Review 1.  Motor disorders of the esophagus.

Authors:  S Cohen
Journal:  N Engl J Med       Date:  1979-07-26       Impact factor: 91.245

2.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

3.  CRST syndrome. A benign variant of scleroderma.

Authors:  R D Carr; E B Heisel; T D Stevenson
Journal:  Arch Dermatol       Date:  1965-11

4.  Surgery for scleroderma of the esophagus: a 12-year experience.

Authors:  K A Mansour; C E Malone
Journal:  Ann Thorac Surg       Date:  1988-11       Impact factor: 4.330

5.  Surgical management of scleroderma reflux esophagitis.

Authors:  M B Orringer
Journal:  Surg Clin North Am       Date:  1983-08       Impact factor: 2.741

6.  Oesophageal changes in systemic sclerosis.

Authors:  M Atkinson; M D Summerling
Journal:  Gut       Date:  1966-08       Impact factor: 23.059

7.  Esophageal motor disorders.

Authors:  R D Henderson
Journal:  Surg Clin North Am       Date:  1987-06       Impact factor: 2.741

8.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

9.  The gastrointestinal manifestations of scleroderma: pathogenesis and management.

Authors:  S Cohen
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

10.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

View more
  4 in total

1.  Antimyenteric neuronal antibodies in scleroderma.

Authors:  S Howe; E Y Eaker; J E Sallustio; C Peebles; E M Tan; R C Williams
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 2.  Effects of Food and Liquid Properties on Swallowing Physiology and Function in Adults.

Authors:  Rodolfo E Peña-Chávez; Nicole E Schaen-Heacock; Mary E Hitchcock; Atsuko Kurosu; Ryo Suzuki; Richard W Hartel; Michelle R Ciucci; Nicole M Rogus-Pulia
Journal:  Dysphagia       Date:  2022-10-20       Impact factor: 2.733

Review 3.  Dysphagia in dermatologic disease.

Authors:  R Bübl; B Schön
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

4.  Gastrointestinal Manifestations of Systemic Sclerosis.

Authors:  Isabel M McFarlane; Manjeet S Bhamra; Alexandra Kreps; Sadat Iqbal; Firas Al-Ani; Carla Saladini-Aponte; Christon Grant; Soberjot Singh; Khalid Awwal; Kristaq Koci; Yair Saperstein; Fray M Arroyo-Mercado; Derek B Laskar; Purna Atluri
Journal:  Rheumatology (Sunnyvale)       Date:  2018-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.